Drug Trial Radar · NCT04838548
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87
Actual
Start
Apr 16, 2021
Primary completion
Mar 27, 2023
Study completion Mar 27, 2023
Sponsor
- Lead sponsor
- Lepu Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the efficacy, safety of MRG003 as single agent in EGFR-positive advanced non-small cell lung cancer
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
MRG003Drug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) by InvestigatorTime frame: Baseline to study completion, up to 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.